Celularity Inc. (CELU) |
|
0.5901 -0.024 (-3.97%)
|
03-17 16:00 |
|
Open: |
0.61 |
Pre. Close: |
0.6145 |
|
High:
|
0.616 |
Low:
|
0.59 |
|
Volume:
|
261,347 |
Market Cap:
|
86(M) |
|
|
|
Technical analysis |
as of: 2023-03-20 7:44:30 AM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 0.86  One year: 0.99 |
| Support: |
Support1: 0.56 Support2: 0.47 |
| Resistance: |
Resistance1: 0.74 Resistance2: 0.85 |
| Pivot: |
0.69 |
| Moving Average: |
MA(5): 0.6 MA(20): 0.68
MA(100): 1.27 MA(250): 3.69 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 15.6  %D(3): 13.6 |
| RSI: |
RSI(14): 35.9 |
| 52-week: |
High: 13.18 Low: 0.56 |
| Average Vol(K): |
3-Month: 621 (K) 10-Days: 405 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ CELU ] has closed above bottom band by 19.2%. Bollinger Bands are 31.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.62 - 0.62 |
0.62 - 0.62 |
|
Low:
|
0.58 - 0.58 |
0.58 - 0.59 |
|
Close:
|
0.58 - 0.59 |
0.59 - 0.6 |
|
Company Description |
|
Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, a placental-derived CAR-T therapy, which is in Phase I clinical trial for the treatment of B-cell malignancies; CYNK-001, placental-derived unmodified natural killer (NK) cell that is in Phase I clinical trial to treat acute myeloid leukemia, as well as in Phase I/IIa clinical trial for the treatment of glioblastoma multiforme and COVID-19; CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I clinical trial to treat HER2+ gastric and gastroesophageal cancers; APPL-001, a placenta-derived mesenchymal-like adherent stromal cell that is in a pre-clinical stage for the treatment of Crohn's disease; and PDA-002, a placenta-derived mesenchymal-like adherent stromal cell, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy. It also sells and licenses products that are used in surgical and wound care markets, such as Biovance and Interfyl; collects stem cells from umbilical cords and placentas; and provides cells storage under the LifebankUSA brand. The company was incorporated in 2016 and is headquartered in Florham Park, New Jersey. |
Headline News |
Fri, 17 Mar 2023
Celularity : VERIFIED PETITIONFOR RELIEF PURSUANTTO 8 Del. C. ยง 205 - Form 8-K - Marketscreener.com
Fri, 17 Mar 2023
Celularity, Inc. (CELU) Is a Trending Stock: Facts to Know Before ... - Nasdaq
Mon, 06 Mar 2023
Celularity (CELU) to Report Q4 Earnings: What's in the Cards? - Nasdaq
Mon, 06 Mar 2023
Investors Heavily Search Celularity, Inc. (CELU): Here is What You ... - Nasdaq
Mon, 20 Feb 2023
Here is What to Know Beyond Why Celularity, Inc. (CELU) is a ... - Nasdaq
Mon, 13 Feb 2023
Celularity, Inc. (CELU) Outpaces Stock Market Gains: What You ... - Yahoo Finance
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Outperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
145 (M) |
| Shares Float |
54 (M) |
|
% Held by Insiders
|
65.1 (%) |
|
% Held by Institutions
|
24.2 (%) |
|
Shares Short
|
3,440 (K) |
|
Shares Short P.Month
|
2,490 (K) |
Stock Financials |
|
EPS
|
0.43 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
1.13 |
|
Profit Margin (%)
|
-76.4 |
|
Operating Margin (%)
|
-760.7 |
|
Return on Assets (ttm)
|
-20.1 |
|
Return on Equity (ttm)
|
-11 |
|
Qtrly Rev. Growth
|
-61.1 |
|
Gross Profit (p.s.)
|
0.08 |
|
Sales Per Share
|
0.12 |
|
EBITDA (p.s.)
|
-0.92 |
|
Qtrly Earnings Growth
|
-92.5 |
|
Operating Cash Flow
|
-140 (M) |
|
Levered Free Cash Flow
|
-71 (M) |
Stock Valuations |
|
PE Ratio
|
1.37 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0.51 |
|
Price to Sales
|
4.57 |
|
Price to Cash Flow
|
-0.61 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
